|1.||Collins, Dorothea: 10 articles (05/2009 - 01/2002)|
|2.||Robins, Sander J: 7 articles (02/2008 - 01/2002)|
|3.||Pahan, Kalipada: 6 articles (11/2012 - 10/2007)|
|4.||Schaefer, Ernst J: 6 articles (01/2008 - 12/2002)|
|5.||Bloomfield, Hanna E: 5 articles (05/2009 - 03/2006)|
|6.||Gonzalez, Frank J: 4 articles (04/2014 - 02/2011)|
|7.||Faas, Fred H: 4 articles (04/2008 - 08/2002)|
|8.||Pasternack, Amos: 4 articles (04/2004 - 03/2002)|
|9.||Taskinen, Marja-Riitta: 4 articles (04/2004 - 03/2002)|
|10.||Frick, M Heikki: 4 articles (04/2004 - 03/2002)|
|1.||Coronary Disease (Coronary Heart Disease)
04/10/2006 - "The Helsinki Heart Study was a double-blind, placebo-controlled primary prevention trial among 4081 dyslipidemic middle-aged men to test the efficacy of gemfibrozil in the prevention of coronary heart disease (CHD). "
02/15/1992 - "The Helsinki Heart Study was a randomized, double-blind, 5-year clinical trial to test the efficacy of gemfibrozil in reducing the risk for coronary heart disease. "
03/01/1995 - "The purpose of the present study was to assess the effect of gemfibrozil on 12 independent coronary heart disease risk factors in patients with primary combined hyperlipidaemia. "
01/01/1995 - "To investigate the influence of antihypertensive therapy and the success of blood pressure control on coronary heart disease incidence and total mortality, we studied dyslipidemic middle-aged men participating in the placebo arm of the Helsinki Heart Study, a randomized coronary primary prevention trial with gemfibrozil. "
01/01/1994 - "All participants of the Helsinki Heart Study (a controlled, 5-year, multi-clinic coronary heart disease (CHD) primary prevention trial with gemfibrozil and placebo) were offered gemfibrozil treatment and twice yearly follow-up for 3.5 years. "
07/01/1998 - "We performed a double-blind, placebo-controlled intervention trial to establish whether gemfibrozil could improve resistance of LDL to oxidation in patients with hyperlipidemia. "
01/01/2010 - "A 46-year-old man with hyperlipidemia was treated with 600 mg gemfibrozil twice a day. "
01/01/2003 - "Forty-six consecutive patients received a statin and gemfibrozil combination for resistant hyperlipidemia to either agent therapy. "
01/01/2003 - "Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature."
01/01/1996 - "Persistence of balloon-induced arterial injury with hyperlipidemia despite gemfibrozil."
11/01/2001 - "Twice daily administration of 600 mg of gemfibrozil is effective in type 2 diabetic patients with associated hypertriglyceridemia. "
08/15/1993 - "In 14 men and nine women referred because of severe primary hypertriglyceridemia, our specific aim in a 54-week single-blind treatment (Rx) period was to determine whether triglyceride (TG) lowering with a Type V diet and Lopid would lead to improvement in symptoms of depression, improvement in an index of life stressors, change in locus of control index, and improved cognition, as serially tested by Beck (BDI), Hassles (HAS) and HAS intensity indices, Locus of Control index, and the Folstein Mini-Mental status exam. "
05/01/1997 - "This study suggests that hypertriglyceridemia is a minor side effect of long-term IFN-alpha therapy and that gemfibrozil might be considered the treatment of choice."
07/01/2015 - "In patients with modest hypertriglyceridemia with lifestyle intervention, APE-H reduced the TG level comparable to the effect of gemfibrozil 300 mg/day. "
07/01/2015 - "paniculata extract (APE) in patients with hypertriglyceridemia (TG ≥ 150 mg/dL) using gemfibrozil treatment as the reference. "
04/01/1996 - "We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia. "
04/01/1996 - "Gemfibrozil treatment of combined hyperlipoproteinemia. "
01/01/1995 - "A placebo-controlled crossover study was conducted to evaluate whether lipid-lowering with gemfibrozil (10 to 12 weeks) affects platelet function in vivo at rest and during mental stress in 21 men with combined hyperlipoproteinemia. "
01/01/1995 - "Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia."
01/01/1991 - "[Gemfibrozil in the treatment of hyperlipoproteinemias]."
04/10/2006 - "Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome."
04/10/2006 - "Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study."
04/01/1993 - "Diet and exercise and gemfibrozil therapy for the management of dyslipidemia: a CEN study. "
11/12/1987 - "Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. "
04/01/2014 - "Gemfibrozil, a ligand of peroxisome proliferator-activated receptor α (PPARα), is one of the most widely prescribed anti-dyslipidemia fibrate drugs. "
|4.||Fibric Acids (Fibrates)
|1.||Transplantation (Transplant Recipients)
|2.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|3.||Homologous Transplantation (Allograft)
|4.||Phototherapy (Light Therapy)